€70 per 1mg
€600 per 10mg
€3.500 per 100mg
VEGF (Vascular endothelial growth factor) is the only growth factor that stimulates vascular permeability. It promotes endothelial proliferation and survival, angiogenesis, vasculognesis and inhibits apoptosis. VEGF mitogenic activity is specific for endothelial cell and that makes it distinct among other growth factors. VEGF is thought to be important in the pathophysiology of neuronal and other tumours, by functioning as a prompter of angiogenesis for human gliomas. Human VEGF occurs in several molecular variants and the 165 form is the most common form in most tissues. Biological activities of VEGF are not species specific and glycosylation is not required for biological activity.
Recombinant MESOkine VEGF165 is produced in the endosperm tissue of barley seed (Hordeum vulgare).
Tris pH 7.4, sterile filtered through 0.2 um filter.
MESOkine recombinant VEGF165 is purified from barley seeds resulting in an extract containing purified recombinant VEGF165 protein along with co-purified barley seed proteins. The amount of the recombinant VEGF165 protein is typically in the range of 20-30% of total purified protein content. The exact content of the growth factor is stated on the vials. The co-purified barley seed proteins serve as stabilizing proteins that can prolong the lifetime of the recombinant protein and may enhance the bioactivity of growth factors in standardized bioassays.
Always centrifuge the vial before opening. It is recommended to reconstitute the lyophilized protein in sterile buffered saline or a solution of your choice, to a concentration of no less than 100 µg/ml. The lyophilized protein, though stable at room temperature for few weeks, is best stored at -20°C. Reconstituted protein should be used immediately or stored in working aliquots at -20°C. Avoid repeated freeze-thaw cycles.
Each batch of MESOkine growth factor is tested for bioactivity and verified to have comparable activity to a corresponding commercial source of highly purified (>95%) growth factor. The bioactivity of MESOkine recombinant human VEGF 165 was determined by its dose dependent effect on proliferation of Human Umbilical Vein Endothelial Cells (HUVEC). The ED50 for this effect is typically below 10 ng/ml corresponding to specific activity of > 1 x 10e5 U/mg. Optimal concentration should be determined for specific applications and cell lines.
Endotoxin levels of each MESOkine is measured and verified to have endotoxin content <0.05 EU/ug.
Recombinant human MESOkine VEGF165 contains 165 amino acids and a 6 a.a. histidine tag for a total length of 171 a.a. and has a predicted molecular mass of 20.0 kDa. As a result of glycosylation, the recombinant protein migrates with an apparent molecular mass of 25 - 27 kDa in SDS-PAGE.